Plaque Psoriasis

Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.

Psoriasis advocates Nitika Chopra and Ayesha Patrick address common misconceptions, how patients can speak up, and simple tips for clinicians.

On World Psoriasis Day, advocates Nitika Chopra and Ayesha Patrick discuss feeling dismissed and what dermatologists should know about skin of color care.

ORKA-001, a half-life extended IL-23p19 antibody, achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B psoriasis trial.

Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.

At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.

A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.

Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.

Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.

Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.

New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.

Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Zasocitinib achieved PASI 100 in 36.5% of patients vs 13.9% with deucravacitinib at week 16 in the phase 3 LATITUDE Atlas psoriasis trial.

Jennifer Soung, MD, and Mona Shahriari, MD, discuss trust-building, psychosocial burden, and treatment fit in psoriasis care for diverse skin tones.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.

In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.

Raj Chovatiya, MD, PhD, discusses how the oral TYK2 inhibitor zasocitinib may affect scalp, nail, and hand psoriasis, clearance speed, and once-daily dosing.

Raj Chovatiya, MD, PhD, explains where oral TYK2 inhibitor zasocitinib may fit in psoriasis treatment after the FDA accepted its NDA under priority review.

Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for a patient with psoriatic arthritis.

New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.

David Oberlin, MD, explains why APEX's enriched trial population, not drug mechanism, likely drove its unique radiographic success in psoriatic arthritis.